Prevalence of Lower Urinary Tract Symptoms in People with Multiple Sclerosis: A Systematic Review and Meta-analysis

Learning Objectives:

1. Provide the pooled prevalence estimates of lower urinary tract symptoms (LUTSs) and LUTS types in the general MS population according to International Continence Society (ICS) classification.
2. Identify limitations in the current evidence base and recommendations for conducting significant future studies.

Accreditation Statement


Physician Credit
The CMSC designates this journal-based activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Credit
The CMSC designates this enduring material for 1.5 contact hour (none in the area of pharmacology).

Disclosures:
Francois Bethoux, MD, Editor in Chief of the International Journal of MS Care (IJMSC), Editor in Chief of the International Journal of MS Care (IJMSC), has served as Physician Planner for this activity. He has disclosed relationships with Springer Publishing (royalty), Qr8 (receipt of intellectual property rights/patent holder), Biogen (receipt of intellectual property rights/patent holder, speakers' bureau), GW Pharma (consulting fee), and Adamas Pharmaceuticals (contracted research).

Laurie Scudder, DNP, NP, has served as Reviewer for this activity. She
has disclosed no relevant financial relationships.

Hawra B. Al Dandan, PT, M App Mngt (Health), has disclosed no relevant
financial relationships.

Susan Coote, PT, PhD, has disclosed a relationship with Novartis (fees for non-CME/CE services received directly from a commercial interest [contractor to deliver telerehabilitation as part of patient support program]).

Doreen McClurg, PT, PhD, has disclosed no relevant financial relationships.

The peer reviewers for IJMSC have disclosed no relevant financial relationships.
The staff at IJMSC, CMSC, and Delaware Media Group who are in a position to influence content have disclosed no relevant financial relationships.

Note: Financial relationships may have changed in the interval between listing these disclosures and publication of the article.

Method of Participation:
Release Date: April 1, 2020; Valid for Credit Through: April 1, 2021

In order to receive CME/CNE credit, participants must:

1) Review the continuing education information, including learning objectives and author disclosures.
2) Study the educational content.
3) Complete the post-test and evaluation.

Statements of Credit are awarded upon successful completion of the post-test with a passing score of >70% and the evaluation. There is no fee to participate in this activity.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. CMSC and Delaware Media Group do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent
the views of CMSC or Delaware Media Group.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health-care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities.